The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Last month, Roche reached a $1.65 billion deal to partner in the development of a Zealand Pharma obesity drug that goes after a different target than the currently available weight management ...

Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes: Copenhagen, Denmark Saturday, April 2 ...

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new ... on late-stage trials and sales development, Roche said at the time. The two companies will ...

With the threat of pharmaceutical tariffs hanging over the biopharmaceutical industry, Roche is the latest addition to a ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

Swiss pharmaceuticals powerhouse Roche says it plans to invest $50 billion in the United States over the next five years and ...

Swiss pharma giant Roche (ROG: SIX) today reported that it achieved sales growth of 6% (7% in francs) to 15.4 billion francs ...

Roche CEO Thomas Schinecker said in a statement on Tuesday that the company’s new $50 billion investment demonstrated its ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...

Enrollment and randomization in ZUPREME-1 was completed in three months. In March 2025, Zealand Pharma and Roche entered a collaboration and license agreement to co-develop and co-commercialize ...